nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexamethasone—Corticosteroid Hormone Receptor Agonists—Prednisone—systemic scleroderma	0.231	1	CiPCiCtD
Dexamethasone—Mometasone—systemic scleroderma	0.141	0.647	CrCtD
Dexamethasone—Prednisone—systemic scleroderma	0.0766	0.353	CrCtD
Dexamethasone—ankylosing spondylitis—systemic scleroderma	0.0643	0.277	CtDrD
Dexamethasone—systemic lupus erythematosus—systemic scleroderma	0.0613	0.264	CtDrD
Dexamethasone—rheumatoid arthritis—systemic scleroderma	0.0579	0.25	CtDrD
Dexamethasone—psoriasis—systemic scleroderma	0.0485	0.209	CtDrD
Dexamethasone—NR3C1—Mometasone—systemic scleroderma	0.0218	0.224	CbGbCtD
Dexamethasone—ABCG2—Leflunomide—systemic scleroderma	0.00908	0.0932	CbGbCtD
Dexamethasone—CYP2C8—Mometasone—systemic scleroderma	0.0075	0.077	CbGbCtD
Dexamethasone—NR3C1—Prednisone—systemic scleroderma	0.00694	0.0713	CbGbCtD
Dexamethasone—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0062	0.0637	CbGbCtD
Dexamethasone—SLCO1A2—Prednisone—systemic scleroderma	0.00598	0.0614	CbGbCtD
Dexamethasone—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.00561	0.0576	CbGbCtD
Dexamethasone—Fluticasone furoate—Mometasone—systemic scleroderma	0.00478	0.0296	CrCrCtD
Dexamethasone—Flumethasone Pivalate—Mometasone—systemic scleroderma	0.0043	0.0266	CrCrCtD
Dexamethasone—Difluprednate—Mometasone—systemic scleroderma	0.00416	0.0257	CrCrCtD
Dexamethasone—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00416	0.0257	CrCrCtD
Dexamethasone—Halobetasol Propionate—Mometasone—systemic scleroderma	0.00416	0.0257	CrCrCtD
Dexamethasone—Prednicarbate—Mometasone—systemic scleroderma	0.00391	0.0242	CrCrCtD
Dexamethasone—Fluocinonide—Mometasone—systemic scleroderma	0.00391	0.0242	CrCrCtD
Dexamethasone—Clocortolone—Mometasone—systemic scleroderma	0.00391	0.0242	CrCrCtD
Dexamethasone—Beclomethasone—Mometasone—systemic scleroderma	0.00391	0.0242	CrCrCtD
Dexamethasone—Testolactone—Mometasone—systemic scleroderma	0.00391	0.0242	CrCrCtD
Dexamethasone—Fluocortolone—Mometasone—systemic scleroderma	0.0038	0.0235	CrCrCtD
Dexamethasone—Fluocinolone Acetonide—Mometasone—systemic scleroderma	0.0037	0.0228	CrCrCtD
Dexamethasone—Alclometasone—Mometasone—systemic scleroderma	0.0037	0.0228	CrCrCtD
Dexamethasone—Amcinonide—Mometasone—systemic scleroderma	0.0036	0.0222	CrCrCtD
Dexamethasone—Budesonide—Mometasone—systemic scleroderma	0.0036	0.0222	CrCrCtD
Dexamethasone—Fluoxymesterone—Mometasone—systemic scleroderma	0.0036	0.0222	CrCrCtD
Dexamethasone—Diflorasone—Mometasone—systemic scleroderma	0.0035	0.0217	CrCrCtD
Dexamethasone—Clobetasol propionate—Mometasone—systemic scleroderma	0.0035	0.0217	CrCrCtD
Dexamethasone—Fludrocortisone—Mometasone—systemic scleroderma	0.0035	0.0217	CrCrCtD
Dexamethasone—Flunisolide—Mometasone—systemic scleroderma	0.0035	0.0217	CrCrCtD
Dexamethasone—Prednisone—Mometasone—systemic scleroderma	0.0035	0.0217	CrCrCtD
Dexamethasone—Desonide—Mometasone—systemic scleroderma	0.0035	0.0217	CrCrCtD
Dexamethasone—ABCB1—Lisinopril—systemic scleroderma	0.00343	0.0352	CbGbCtD
Dexamethasone—Paramethasone—Mometasone—systemic scleroderma	0.00342	0.0211	CrCrCtD
Dexamethasone—CYP2C9—Leflunomide—systemic scleroderma	0.00337	0.0346	CbGbCtD
Dexamethasone—Desoximetasone—Mometasone—systemic scleroderma	0.00333	0.0206	CrCrCtD
Dexamethasone—Loteprednol—Mometasone—systemic scleroderma	0.00325	0.0201	CrCrCtD
Dexamethasone—Triamcinolone—Mometasone—systemic scleroderma	0.00325	0.0201	CrCrCtD
Dexamethasone—Fluprednidene Acetate—Mometasone—systemic scleroderma	0.00325	0.0201	CrCrCtD
Dexamethasone—Fluorometholone—Mometasone—systemic scleroderma	0.00325	0.0201	CrCrCtD
Dexamethasone—Betamethasone—Mometasone—systemic scleroderma	0.00318	0.0197	CrCrCtD
Dexamethasone—Rimexolone—Mometasone—systemic scleroderma	0.00318	0.0197	CrCrCtD
Dexamethasone—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.00311	0.0319	CbGbCtD
Dexamethasone—Methylprednisolone—Mometasone—systemic scleroderma	0.00304	0.0188	CrCrCtD
Dexamethasone—SLCO1A2—Methotrexate—systemic scleroderma	0.003	0.0308	CbGbCtD
Dexamethasone—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.00299	0.0307	CbGbCtD
Dexamethasone—Prednisolone—Mometasone—systemic scleroderma	0.00298	0.0184	CrCrCtD
Dexamethasone—Hydrocortisone—Mometasone—systemic scleroderma	0.00286	0.0177	CrCrCtD
Dexamethasone—ABCB1—Captopril—systemic scleroderma	0.00257	0.0264	CbGbCtD
Dexamethasone—ABCC2—Methotrexate—systemic scleroderma	0.00249	0.0255	CbGbCtD
Dexamethasone—CYP2D6—Captopril—systemic scleroderma	0.00242	0.0248	CbGbCtD
Dexamethasone—ABCG2—Methotrexate—systemic scleroderma	0.00225	0.0231	CbGbCtD
Dexamethasone—Prednicarbate—Prednisone—systemic scleroderma	0.00213	0.0132	CrCrCtD
Dexamethasone—Testolactone—Prednisone—systemic scleroderma	0.00213	0.0132	CrCrCtD
Dexamethasone—Fluocortolone—Prednisone—systemic scleroderma	0.00207	0.0128	CrCrCtD
Dexamethasone—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00202	0.0208	CbGbCtD
Dexamethasone—Alclometasone—Prednisone—systemic scleroderma	0.00201	0.0124	CrCrCtD
Dexamethasone—CYP2C19—Prednisone—systemic scleroderma	0.002	0.0206	CbGbCtD
Dexamethasone—Budesonide—Prednisone—systemic scleroderma	0.00196	0.0121	CrCrCtD
Dexamethasone—Amcinonide—Prednisone—systemic scleroderma	0.00196	0.0121	CrCrCtD
Dexamethasone—Fludrocortisone—Prednisone—systemic scleroderma	0.00191	0.0118	CrCrCtD
Dexamethasone—Diflorasone—Prednisone—systemic scleroderma	0.00191	0.0118	CrCrCtD
Dexamethasone—Flunisolide—Prednisone—systemic scleroderma	0.00191	0.0118	CrCrCtD
Dexamethasone—Desonide—Prednisone—systemic scleroderma	0.00191	0.0118	CrCrCtD
Dexamethasone—Clobetasol propionate—Prednisone—systemic scleroderma	0.00191	0.0118	CrCrCtD
Dexamethasone—Paramethasone—Prednisone—systemic scleroderma	0.00186	0.0115	CrCrCtD
Dexamethasone—Desoximetasone—Prednisone—systemic scleroderma	0.00182	0.0112	CrCrCtD
Dexamethasone—Loteprednol—Prednisone—systemic scleroderma	0.00177	0.011	CrCrCtD
Dexamethasone—Mometasone—Prednisone—systemic scleroderma	0.00177	0.011	CrCrCtD
Dexamethasone—Triamcinolone—Prednisone—systemic scleroderma	0.00177	0.011	CrCrCtD
Dexamethasone—Fluprednidene Acetate—Prednisone—systemic scleroderma	0.00177	0.011	CrCrCtD
Dexamethasone—Fluorometholone—Prednisone—systemic scleroderma	0.00177	0.011	CrCrCtD
Dexamethasone—Rimexolone—Prednisone—systemic scleroderma	0.00173	0.0107	CrCrCtD
Dexamethasone—Betamethasone—Prednisone—systemic scleroderma	0.00173	0.0107	CrCrCtD
Dexamethasone—Methylprednisolone—Prednisone—systemic scleroderma	0.00166	0.0102	CrCrCtD
Dexamethasone—Prednisolone—Prednisone—systemic scleroderma	0.00162	0.01	CrCrCtD
Dexamethasone—ABCB1—Prednisone—systemic scleroderma	0.00162	0.0166	CbGbCtD
Dexamethasone—Hydrocortisone—Prednisone—systemic scleroderma	0.00156	0.00963	CrCrCtD
Dexamethasone—CYP2C9—cardial valve—systemic scleroderma	0.0013	0.124	CbGeAlD
Dexamethasone—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00121	0.0124	CbGbCtD
Dexamethasone—CYP3A4—Prednisone—systemic scleroderma	0.000968	0.00994	CbGbCtD
Dexamethasone—ABCB1—Methotrexate—systemic scleroderma	0.000811	0.00833	CbGbCtD
Dexamethasone—PLA2G1B—blood vessel—systemic scleroderma	0.000578	0.0552	CbGeAlD
Dexamethasone—NOS2—tendon—systemic scleroderma	0.000535	0.0511	CbGeAlD
Dexamethasone—PTGS2—skeletal joint—systemic scleroderma	0.000407	0.0389	CbGeAlD
Dexamethasone—PGR—artery—systemic scleroderma	0.000341	0.0326	CbGeAlD
Dexamethasone—PLA2G1B—connective tissue—systemic scleroderma	0.000296	0.0283	CbGeAlD
Dexamethasone—PGR—blood vessel—systemic scleroderma	0.000266	0.0254	CbGeAlD
Dexamethasone—CYP4A11—digestive system—systemic scleroderma	0.000258	0.0247	CbGeAlD
Dexamethasone—NR0B1—lung—systemic scleroderma	0.000251	0.0239	CbGeAlD
Dexamethasone—ANXA1—connective tissue—systemic scleroderma	0.000226	0.0216	CbGeAlD
Dexamethasone—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.000221	0.624	CbGdCrCtD
Dexamethasone—PLA2G1B—digestive system—systemic scleroderma	0.000214	0.0204	CbGeAlD
Dexamethasone—ANXA1—smooth muscle tissue—systemic scleroderma	0.000207	0.0198	CbGeAlD
Dexamethasone—ANXA1—skin of body—systemic scleroderma	0.000204	0.0195	CbGeAlD
Dexamethasone—CYP17A1—connective tissue—systemic scleroderma	0.000203	0.0194	CbGeAlD
Dexamethasone—CYP11A1—connective tissue—systemic scleroderma	0.000189	0.018	CbGeAlD
Dexamethasone—PLA2G1B—lung—systemic scleroderma	0.000179	0.0171	CbGeAlD
Dexamethasone—PTGS2—artery—systemic scleroderma	0.00017	0.0163	CbGeAlD
Dexamethasone—ABCB11—digestive system—systemic scleroderma	0.000166	0.0159	CbGeAlD
Dexamethasone—ANXA1—digestive system—systemic scleroderma	0.000164	0.0156	CbGeAlD
Dexamethasone—ANXA1—tendon—systemic scleroderma	0.000156	0.0149	CbGeAlD
Dexamethasone—NR3C2—connective tissue—systemic scleroderma	0.000147	0.014	CbGeAlD
Dexamethasone—PTGS2—endothelium—systemic scleroderma	0.000144	0.0138	CbGeAlD
Dexamethasone—ANXA1—lung—systemic scleroderma	0.000137	0.013	CbGeAlD
Dexamethasone—PGR—connective tissue—systemic scleroderma	0.000136	0.013	CbGeAlD
Dexamethasone—NR3C2—smooth muscle tissue—systemic scleroderma	0.000134	0.0128	CbGeAlD
Dexamethasone—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000134	0.376	CbGdCrCtD
Dexamethasone—PTGS2—blood vessel—systemic scleroderma	0.000133	0.0127	CbGeAlD
Dexamethasone—PGR—smooth muscle tissue—systemic scleroderma	0.000125	0.0119	CbGeAlD
Dexamethasone—CYP19A1—connective tissue—systemic scleroderma	0.000123	0.0117	CbGeAlD
Dexamethasone—CYP1B1—connective tissue—systemic scleroderma	0.000115	0.011	CbGeAlD
Dexamethasone—NR3C2—digestive system—systemic scleroderma	0.000106	0.0101	CbGeAlD
Dexamethasone—CYP1B1—smooth muscle tissue—systemic scleroderma	0.000105	0.01	CbGeAlD
Dexamethasone—CYP1B1—skin of body—systemic scleroderma	0.000104	0.00989	CbGeAlD
Dexamethasone—NR3C2—tendon—systemic scleroderma	0.000101	0.00963	CbGeAlD
Dexamethasone—CYP2A6—lung—systemic scleroderma	9.44e-05	0.00901	CbGeAlD
Dexamethasone—SLCO1A2—digestive system—systemic scleroderma	9.08e-05	0.00867	CbGeAlD
Dexamethasone—NR3C2—lung—systemic scleroderma	8.85e-05	0.00845	CbGeAlD
Dexamethasone—ABCC2—digestive system—systemic scleroderma	8.46e-05	0.00808	CbGeAlD
Dexamethasone—CYP1B1—digestive system—systemic scleroderma	8.28e-05	0.00791	CbGeAlD
Dexamethasone—PGR—lung—systemic scleroderma	8.22e-05	0.00785	CbGeAlD
Dexamethasone—ABCB1—blood vessel—systemic scleroderma	8.21e-05	0.00784	CbGeAlD
Dexamethasone—ABCC2—tendon—systemic scleroderma	8.05e-05	0.00769	CbGeAlD
Dexamethasone—CYP1B1—tendon—systemic scleroderma	7.88e-05	0.00753	CbGeAlD
Dexamethasone—NR3C1—connective tissue—systemic scleroderma	7.87e-05	0.00751	CbGeAlD
Dexamethasone—SLCO1A2—lung—systemic scleroderma	7.58e-05	0.00724	CbGeAlD
Dexamethasone—CYP1A1—skin of body—systemic scleroderma	7.32e-05	0.00699	CbGeAlD
Dexamethasone—CYP2C19—digestive system—systemic scleroderma	7.27e-05	0.00694	CbGeAlD
Dexamethasone—NR3C1—smooth muscle tissue—systemic scleroderma	7.2e-05	0.00687	CbGeAlD
Dexamethasone—CYP2B6—skin of body—systemic scleroderma	7.11e-05	0.00679	CbGeAlD
Dexamethasone—NR3C1—skin of body—systemic scleroderma	7.1e-05	0.00678	CbGeAlD
Dexamethasone—CYP1B1—lung—systemic scleroderma	6.92e-05	0.00661	CbGeAlD
Dexamethasone—PTGS2—connective tissue—systemic scleroderma	6.81e-05	0.0065	CbGeAlD
Dexamethasone—PTGS2—smooth muscle tissue—systemic scleroderma	6.23e-05	0.00595	CbGeAlD
Dexamethasone—PTGS2—skin of body—systemic scleroderma	6.15e-05	0.00587	CbGeAlD
Dexamethasone—CYP1A1—digestive system—systemic scleroderma	5.86e-05	0.00559	CbGeAlD
Dexamethasone—CYP3A5—digestive system—systemic scleroderma	5.73e-05	0.00547	CbGeAlD
Dexamethasone—CYP2B6—digestive system—systemic scleroderma	5.69e-05	0.00543	CbGeAlD
Dexamethasone—NR3C1—digestive system—systemic scleroderma	5.68e-05	0.00543	CbGeAlD
Dexamethasone—CYP2C9—digestive system—systemic scleroderma	5.63e-05	0.00538	CbGeAlD
Dexamethasone—NR3C1—tendon—systemic scleroderma	5.41e-05	0.00516	CbGeAlD
Dexamethasone—CYP2E1—digestive system—systemic scleroderma	5.34e-05	0.0051	CbGeAlD
Dexamethasone—ABCG2—lung—systemic scleroderma	5.15e-05	0.00492	CbGeAlD
Dexamethasone—CYP2E1—tendon—systemic scleroderma	5.08e-05	0.00485	CbGeAlD
Dexamethasone—PTGS2—digestive system—systemic scleroderma	4.92e-05	0.0047	CbGeAlD
Dexamethasone—CYP1A1—lung—systemic scleroderma	4.89e-05	0.00467	CbGeAlD
Dexamethasone—CYP3A5—lung—systemic scleroderma	4.78e-05	0.00457	CbGeAlD
Dexamethasone—CYP2B6—lung—systemic scleroderma	4.75e-05	0.00454	CbGeAlD
Dexamethasone—NR3C1—lung—systemic scleroderma	4.74e-05	0.00453	CbGeAlD
Dexamethasone—PTGS2—tendon—systemic scleroderma	4.68e-05	0.00447	CbGeAlD
Dexamethasone—NR0B1—Generic Transcription Pathway—SMAD7—systemic scleroderma	4.61e-05	0.00759	CbGpPWpGaD
Dexamethasone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	4.56e-05	0.00751	CbGpPWpGaD
Dexamethasone—ANXA1—Spinal Cord Injury—IL1A—systemic scleroderma	4.56e-05	0.0075	CbGpPWpGaD
Dexamethasone—NOS2—IL23-mediated signaling events—IL1B—systemic scleroderma	4.53e-05	0.00746	CbGpPWpGaD
Dexamethasone—NOS2—Type II interferon signaling (IFNG)—IL1B—systemic scleroderma	4.53e-05	0.00746	CbGpPWpGaD
Dexamethasone—CYP2E1—lung—systemic scleroderma	4.46e-05	0.00426	CbGeAlD
Dexamethasone—CYP3A4—digestive system—systemic scleroderma	4.3e-05	0.0041	CbGeAlD
Dexamethasone—CYP2D6—digestive system—systemic scleroderma	4.23e-05	0.00404	CbGeAlD
Dexamethasone—PTGS2—lung—systemic scleroderma	4.11e-05	0.00392	CbGeAlD
Dexamethasone—NR3C1—AP-1 transcription factor network—COL1A2—systemic scleroderma	4.06e-05	0.00669	CbGpPWpGaD
Dexamethasone—NOS2—ATF-2 transcription factor network—MMP2—systemic scleroderma	3.92e-05	0.00645	CbGpPWpGaD
Dexamethasone—CYP4A11—PPARA activates gene expression—CTGF—systemic scleroderma	3.64e-05	0.00599	CbGpPWpGaD
Dexamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	3.62e-05	0.00595	CbGpPWpGaD
Dexamethasone—NOS2—AGE/RAGE pathway—MMP2—systemic scleroderma	3.58e-05	0.00589	CbGpPWpGaD
Dexamethasone—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	3.56e-05	0.00586	CbGpPWpGaD
Dexamethasone—NR3C2—Generic Transcription Pathway—SMAD7—systemic scleroderma	3.52e-05	0.0058	CbGpPWpGaD
Dexamethasone—NOS2—Spinal Cord Injury—IL1A—systemic scleroderma	3.44e-05	0.00566	CbGpPWpGaD
Dexamethasone—CYP19A1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	3.42e-05	0.00562	CbGpPWpGaD
Dexamethasone—NOS2—AGE/RAGE pathway—NOS3—systemic scleroderma	3.35e-05	0.00552	CbGpPWpGaD
Dexamethasone—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	3.34e-05	0.00549	CbGpPWpGaD
Dexamethasone—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	3.28e-05	0.00541	CbGpPWpGaD
Dexamethasone—ANXA1—G alpha (q) signalling events—EDN1—systemic scleroderma	3.17e-05	0.00522	CbGpPWpGaD
Dexamethasone—ANXA1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	3.16e-05	0.00521	CbGpPWpGaD
Dexamethasone—ANXA1—Spinal Cord Injury—CCL2—systemic scleroderma	3.13e-05	0.00516	CbGpPWpGaD
Dexamethasone—ANXA1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	3.13e-05	0.00516	CbGpPWpGaD
Dexamethasone—NOS2—IL12-mediated signaling events—IL1B—systemic scleroderma	3.08e-05	0.00507	CbGpPWpGaD
Dexamethasone—NR3C1—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	3.06e-05	0.00504	CbGpPWpGaD
Dexamethasone—ABCB1—digestive system—systemic scleroderma	3.04e-05	0.00291	CbGeAlD
Dexamethasone—CYP1A1—Melatonin metabolism and effects—EDN1—systemic scleroderma	2.99e-05	0.00493	CbGpPWpGaD
Dexamethasone—NOS2—Platelet homeostasis—NOS3—systemic scleroderma	2.93e-05	0.00483	CbGpPWpGaD
Dexamethasone—ANXA1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	2.84e-05	0.00467	CbGpPWpGaD
Dexamethasone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	2.77e-05	0.00457	CbGpPWpGaD
Dexamethasone—NOS2—AGE/RAGE pathway—MMP9—systemic scleroderma	2.69e-05	0.00443	CbGpPWpGaD
Dexamethasone—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	2.66e-05	0.00438	CbGpPWpGaD
Dexamethasone—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	2.58e-05	0.00425	CbGpPWpGaD
Dexamethasone—NR0B1—Generic Transcription Pathway—CTGF—systemic scleroderma	2.55e-05	0.0042	CbGpPWpGaD
Dexamethasone—ABCB1—lung—systemic scleroderma	2.54e-05	0.00243	CbGeAlD
Dexamethasone—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	2.45e-05	0.00404	CbGpPWpGaD
Dexamethasone—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	2.45e-05	0.00403	CbGpPWpGaD
Dexamethasone—ANXA1—Spinal Cord Injury—IL1B—systemic scleroderma	2.38e-05	0.00391	CbGpPWpGaD
Dexamethasone—NOS2—Spinal Cord Injury—CCL2—systemic scleroderma	2.36e-05	0.00389	CbGpPWpGaD
Dexamethasone—PLA2G1B—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.36e-05	0.00389	CbGpPWpGaD
Dexamethasone—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	2.3e-05	0.00379	CbGpPWpGaD
Dexamethasone—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	2.29e-05	0.00377	CbGpPWpGaD
Dexamethasone—NOS2—Hemostasis—SELP—systemic scleroderma	2.26e-05	0.00373	CbGpPWpGaD
Dexamethasone—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	2.25e-05	0.00371	CbGpPWpGaD
Dexamethasone—ANXA1—Spinal Cord Injury—MMP9—systemic scleroderma	2.24e-05	0.00369	CbGpPWpGaD
Dexamethasone—NR0B1—Gene Expression—SMAD7—systemic scleroderma	2.22e-05	0.00366	CbGpPWpGaD
Dexamethasone—NR3C1—AP-1 transcription factor network—EDN1—systemic scleroderma	2.2e-05	0.00362	CbGpPWpGaD
Dexamethasone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	2.16e-05	0.00355	CbGpPWpGaD
Dexamethasone—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	2.15e-05	0.00354	CbGpPWpGaD
Dexamethasone—Gastrointestinal disorder—Azathioprine—systemic scleroderma	2.15e-05	0.000488	CcSEcCtD
Dexamethasone—PGR—Generic Transcription Pathway—SMAD7—systemic scleroderma	2.14e-05	0.00353	CbGpPWpGaD
Dexamethasone—ANXA1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	2.14e-05	0.00352	CbGpPWpGaD
Dexamethasone—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	2.14e-05	0.000487	CcSEcCtD
Dexamethasone—Anorexia—Mycophenolic acid—systemic scleroderma	2.14e-05	0.000486	CcSEcCtD
Dexamethasone—Insomnia—Leflunomide—systemic scleroderma	2.13e-05	0.000483	CcSEcCtD
Dexamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	2.12e-05	0.00349	CbGpPWpGaD
Dexamethasone—NOS2—Hemostasis—RHOB—systemic scleroderma	2.11e-05	0.00348	CbGpPWpGaD
Dexamethasone—Paraesthesia—Leflunomide—systemic scleroderma	2.11e-05	0.00048	CcSEcCtD
Dexamethasone—Anaphylactoid reaction—Methotrexate—systemic scleroderma	2.11e-05	0.000479	CcSEcCtD
Dexamethasone—Myalgia—Lisinopril—systemic scleroderma	2.11e-05	0.000479	CcSEcCtD
Dexamethasone—ANXA1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	2.1e-05	0.00346	CbGpPWpGaD
Dexamethasone—Anxiety—Lisinopril—systemic scleroderma	2.1e-05	0.000477	CcSEcCtD
Dexamethasone—Hypotension—Mycophenolic acid—systemic scleroderma	2.09e-05	0.000476	CcSEcCtD
Dexamethasone—Discomfort—Lisinopril—systemic scleroderma	2.08e-05	0.000473	CcSEcCtD
Dexamethasone—Lethargy—Methotrexate—systemic scleroderma	2.08e-05	0.000473	CcSEcCtD
Dexamethasone—Dyspepsia—Leflunomide—systemic scleroderma	2.07e-05	0.00047	CcSEcCtD
Dexamethasone—NR0B1—Gene Expression—TNFSF13—systemic scleroderma	2.06e-05	0.0034	CbGpPWpGaD
Dexamethasone—Vomiting—Mometasone—systemic scleroderma	2.06e-05	0.000469	CcSEcCtD
Dexamethasone—Sweating increased—Prednisone—systemic scleroderma	2.05e-05	0.000467	CcSEcCtD
Dexamethasone—Feeling abnormal—Azathioprine—systemic scleroderma	2.05e-05	0.000466	CcSEcCtD
Dexamethasone—Rash—Mometasone—systemic scleroderma	2.05e-05	0.000465	CcSEcCtD
Dexamethasone—Asthenia—Captopril—systemic scleroderma	2.05e-05	0.000465	CcSEcCtD
Dexamethasone—Dermatitis—Mometasone—systemic scleroderma	2.04e-05	0.000465	CcSEcCtD
Dexamethasone—Decreased appetite—Leflunomide—systemic scleroderma	2.04e-05	0.000464	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	2.04e-05	0.000464	CcSEcCtD
Dexamethasone—Osteoarthritis—Methotrexate—systemic scleroderma	2.04e-05	0.000463	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Azathioprine—systemic scleroderma	2.03e-05	0.000462	CcSEcCtD
Dexamethasone—Headache—Mometasone—systemic scleroderma	2.03e-05	0.000462	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Leflunomide—systemic scleroderma	2.03e-05	0.000461	CcSEcCtD
Dexamethasone—Insomnia—Mycophenolic acid—systemic scleroderma	2.03e-05	0.000461	CcSEcCtD
Dexamethasone—Fatigue—Leflunomide—systemic scleroderma	2.03e-05	0.00046	CcSEcCtD
Dexamethasone—Anaphylactic shock—Lisinopril—systemic scleroderma	2.02e-05	0.000459	CcSEcCtD
Dexamethasone—Oedema—Lisinopril—systemic scleroderma	2.02e-05	0.000459	CcSEcCtD
Dexamethasone—Pruritus—Captopril—systemic scleroderma	2.02e-05	0.000458	CcSEcCtD
Dexamethasone—Paraesthesia—Mycophenolic acid—systemic scleroderma	2.01e-05	0.000457	CcSEcCtD
Dexamethasone—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	2.01e-05	0.000457	CcSEcCtD
Dexamethasone—Pain—Leflunomide—systemic scleroderma	2.01e-05	0.000457	CcSEcCtD
Dexamethasone—Infection—Lisinopril—systemic scleroderma	2.01e-05	0.000456	CcSEcCtD
Dexamethasone—Shock—Lisinopril—systemic scleroderma	1.99e-05	0.000451	CcSEcCtD
Dexamethasone—Angioedema—Mycophenolate mofetil—systemic scleroderma	1.98e-05	0.00045	CcSEcCtD
Dexamethasone—Thrombocytopenia—Lisinopril—systemic scleroderma	1.98e-05	0.000449	CcSEcCtD
Dexamethasone—Dyspepsia—Mycophenolic acid—systemic scleroderma	1.97e-05	0.000448	CcSEcCtD
Dexamethasone—Tachycardia—Lisinopril—systemic scleroderma	1.97e-05	0.000448	CcSEcCtD
Dexamethasone—Body temperature increased—Azathioprine—systemic scleroderma	1.97e-05	0.000447	CcSEcCtD
Dexamethasone—Abdominal pain—Azathioprine—systemic scleroderma	1.97e-05	0.000447	CcSEcCtD
Dexamethasone—Malaise—Mycophenolate mofetil—systemic scleroderma	1.95e-05	0.000444	CcSEcCtD
Dexamethasone—Hyperhidrosis—Lisinopril—systemic scleroderma	1.95e-05	0.000444	CcSEcCtD
Dexamethasone—Diarrhoea—Captopril—systemic scleroderma	1.95e-05	0.000443	CcSEcCtD
Dexamethasone—Decreased appetite—Mycophenolic acid—systemic scleroderma	1.95e-05	0.000443	CcSEcCtD
Dexamethasone—Vertigo—Mycophenolate mofetil—systemic scleroderma	1.95e-05	0.000443	CcSEcCtD
Dexamethasone—NR3C2—Generic Transcription Pathway—CTGF—systemic scleroderma	1.95e-05	0.0032	CbGpPWpGaD
Dexamethasone—Irritability—Methotrexate—systemic scleroderma	1.95e-05	0.000442	CcSEcCtD
Dexamethasone—Syncope—Mycophenolate mofetil—systemic scleroderma	1.94e-05	0.000442	CcSEcCtD
Dexamethasone—Feeling abnormal—Leflunomide—systemic scleroderma	1.94e-05	0.00044	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	1.94e-05	0.00044	CcSEcCtD
Dexamethasone—Fatigue—Mycophenolic acid—systemic scleroderma	1.93e-05	0.000439	CcSEcCtD
Dexamethasone—Mood swings—Methotrexate—systemic scleroderma	1.93e-05	0.000439	CcSEcCtD
Dexamethasone—Nausea—Mometasone—systemic scleroderma	1.93e-05	0.000438	CcSEcCtD
Dexamethasone—NOS2—Hemostasis—CSK—systemic scleroderma	1.92e-05	0.00317	CbGpPWpGaD
Dexamethasone—Anorexia—Lisinopril—systemic scleroderma	1.92e-05	0.000437	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Leflunomide—systemic scleroderma	1.92e-05	0.000437	CcSEcCtD
Dexamethasone—Weight increased—Prednisone—systemic scleroderma	1.92e-05	0.000436	CcSEcCtD
Dexamethasone—Pain—Mycophenolic acid—systemic scleroderma	1.92e-05	0.000436	CcSEcCtD
Dexamethasone—Weight decreased—Prednisone—systemic scleroderma	1.91e-05	0.000434	CcSEcCtD
Dexamethasone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	1.91e-05	0.000433	CcSEcCtD
Dexamethasone—Hyperglycaemia—Prednisone—systemic scleroderma	1.9e-05	0.000432	CcSEcCtD
Dexamethasone—Hypotension—Lisinopril—systemic scleroderma	1.89e-05	0.000429	CcSEcCtD
Dexamethasone—Dizziness—Captopril—systemic scleroderma	1.89e-05	0.000428	CcSEcCtD
Dexamethasone—Convulsion—Mycophenolate mofetil—systemic scleroderma	1.88e-05	0.000427	CcSEcCtD
Dexamethasone—Hypertension—Mycophenolate mofetil—systemic scleroderma	1.87e-05	0.000425	CcSEcCtD
Dexamethasone—Urticaria—Leflunomide—systemic scleroderma	1.87e-05	0.000424	CcSEcCtD
Dexamethasone—Abdominal pain—Leflunomide—systemic scleroderma	1.86e-05	0.000422	CcSEcCtD
Dexamethasone—Body temperature increased—Leflunomide—systemic scleroderma	1.86e-05	0.000422	CcSEcCtD
Dexamethasone—Acute coronary syndrome—Prednisone—systemic scleroderma	1.85e-05	0.000421	CcSEcCtD
Dexamethasone—NR3C1—AP-1 transcription factor network—MMP1—systemic scleroderma	1.85e-05	0.00304	CbGpPWpGaD
Dexamethasone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	1.85e-05	0.00042	CcSEcCtD
Dexamethasone—ANXA1—Spinal Cord Injury—TGFB1—systemic scleroderma	1.85e-05	0.00304	CbGpPWpGaD
Dexamethasone—Myalgia—Mycophenolate mofetil—systemic scleroderma	1.85e-05	0.000419	CcSEcCtD
Dexamethasone—CYP11A1—Corticotropin-releasing hormone—NOS3—systemic scleroderma	1.84e-05	0.00304	CbGpPWpGaD
Dexamethasone—Neuropathy peripheral—Prednisone—systemic scleroderma	1.84e-05	0.000419	CcSEcCtD
Dexamethasone—Myocardial infarction—Prednisone—systemic scleroderma	1.84e-05	0.000419	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	1.84e-05	0.000418	CcSEcCtD
Dexamethasone—Anxiety—Mycophenolate mofetil—systemic scleroderma	1.84e-05	0.000418	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	1.83e-05	0.000417	CcSEcCtD
Dexamethasone—NR3C1—SIDS Susceptibility Pathways—IL13—systemic scleroderma	1.83e-05	0.00301	CbGpPWpGaD
Dexamethasone—Insomnia—Lisinopril—systemic scleroderma	1.83e-05	0.000415	CcSEcCtD
Dexamethasone—Discomfort—Mycophenolate mofetil—systemic scleroderma	1.82e-05	0.000414	CcSEcCtD
Dexamethasone—Paraesthesia—Lisinopril—systemic scleroderma	1.81e-05	0.000412	CcSEcCtD
Dexamethasone—Vomiting—Captopril—systemic scleroderma	1.81e-05	0.000412	CcSEcCtD
Dexamethasone—NOS2—Hemostasis—ITGAM—systemic scleroderma	1.81e-05	0.00298	CbGpPWpGaD
Dexamethasone—Rash—Captopril—systemic scleroderma	1.8e-05	0.000409	CcSEcCtD
Dexamethasone—Dermatitis—Captopril—systemic scleroderma	1.8e-05	0.000408	CcSEcCtD
Dexamethasone—NOS2—Spinal Cord Injury—IL1B—systemic scleroderma	1.79e-05	0.00295	CbGpPWpGaD
Dexamethasone—PLA2G1B—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.79e-05	0.00295	CbGpPWpGaD
Dexamethasone—Headache—Captopril—systemic scleroderma	1.79e-05	0.000406	CcSEcCtD
Dexamethasone—Dyspepsia—Lisinopril—systemic scleroderma	1.78e-05	0.000404	CcSEcCtD
Dexamethasone—Abdominal pain—Mycophenolic acid—systemic scleroderma	1.77e-05	0.000403	CcSEcCtD
Dexamethasone—Body temperature increased—Mycophenolic acid—systemic scleroderma	1.77e-05	0.000403	CcSEcCtD
Dexamethasone—ANXA1—GPCR downstream signaling—RHOB—systemic scleroderma	1.77e-05	0.00291	CbGpPWpGaD
Dexamethasone—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	1.77e-05	0.000402	CcSEcCtD
Dexamethasone—Oedema—Mycophenolate mofetil—systemic scleroderma	1.77e-05	0.000402	CcSEcCtD
Dexamethasone—Infection—Mycophenolate mofetil—systemic scleroderma	1.76e-05	0.000399	CcSEcCtD
Dexamethasone—Decreased appetite—Lisinopril—systemic scleroderma	1.76e-05	0.000399	CcSEcCtD
Dexamethasone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	1.74e-05	0.00287	CbGpPWpGaD
Dexamethasone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	1.74e-05	0.000396	CcSEcCtD
Dexamethasone—Fatigue—Lisinopril—systemic scleroderma	1.74e-05	0.000396	CcSEcCtD
Dexamethasone—Shock—Mycophenolate mofetil—systemic scleroderma	1.74e-05	0.000396	CcSEcCtD
Dexamethasone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	1.73e-05	0.000394	CcSEcCtD
Dexamethasone—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	1.73e-05	0.000394	CcSEcCtD
Dexamethasone—Pain—Lisinopril—systemic scleroderma	1.73e-05	0.000392	CcSEcCtD
Dexamethasone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	1.73e-05	0.000392	CcSEcCtD
Dexamethasone—Bradycardia—Prednisone—systemic scleroderma	1.72e-05	0.000391	CcSEcCtD
Dexamethasone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	1.71e-05	0.000389	CcSEcCtD
Dexamethasone—Diarrhoea—Azathioprine—systemic scleroderma	1.7e-05	0.000387	CcSEcCtD
Dexamethasone—Haemoglobin—Prednisone—systemic scleroderma	1.7e-05	0.000386	CcSEcCtD
Dexamethasone—ABCB1—Allograft Rejection—IL13—systemic scleroderma	1.7e-05	0.00279	CbGpPWpGaD
Dexamethasone—NR3C2—Gene Expression—SMAD7—systemic scleroderma	1.7e-05	0.00279	CbGpPWpGaD
Dexamethasone—Nausea—Captopril—systemic scleroderma	1.69e-05	0.000385	CcSEcCtD
Dexamethasone—NOS2—Spinal Cord Injury—MMP9—systemic scleroderma	1.69e-05	0.00278	CbGpPWpGaD
Dexamethasone—Haemorrhage—Prednisone—systemic scleroderma	1.69e-05	0.000384	CcSEcCtD
Dexamethasone—Anorexia—Mycophenolate mofetil—systemic scleroderma	1.69e-05	0.000383	CcSEcCtD
Dexamethasone—Asthenia—Leflunomide—systemic scleroderma	1.69e-05	0.000383	CcSEcCtD
Dexamethasone—Hallucination—Prednisone—systemic scleroderma	1.68e-05	0.000382	CcSEcCtD
Dexamethasone—Feeling abnormal—Lisinopril—systemic scleroderma	1.66e-05	0.000378	CcSEcCtD
Dexamethasone—Pruritus—Leflunomide—systemic scleroderma	1.66e-05	0.000378	CcSEcCtD
Dexamethasone—Hypotension—Mycophenolate mofetil—systemic scleroderma	1.65e-05	0.000376	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Lisinopril—systemic scleroderma	1.65e-05	0.000375	CcSEcCtD
Dexamethasone—Dizziness—Azathioprine—systemic scleroderma	1.65e-05	0.000374	CcSEcCtD
Dexamethasone—NR3C1—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	1.63e-05	0.00268	CbGpPWpGaD
Dexamethasone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	1.61e-05	0.000366	CcSEcCtD
Dexamethasone—Asthenia—Mycophenolic acid—systemic scleroderma	1.61e-05	0.000366	CcSEcCtD
Dexamethasone—ANXA1—Signaling by GPCR—RHOB—systemic scleroderma	1.61e-05	0.00265	CbGpPWpGaD
Dexamethasone—Diarrhoea—Leflunomide—systemic scleroderma	1.61e-05	0.000365	CcSEcCtD
Dexamethasone—Urticaria—Lisinopril—systemic scleroderma	1.6e-05	0.000365	CcSEcCtD
Dexamethasone—Insomnia—Mycophenolate mofetil—systemic scleroderma	1.6e-05	0.000364	CcSEcCtD
Dexamethasone—ANXA1—GPCR ligand binding—EDN1—systemic scleroderma	1.6e-05	0.00263	CbGpPWpGaD
Dexamethasone—Abdominal pain—Lisinopril—systemic scleroderma	1.6e-05	0.000363	CcSEcCtD
Dexamethasone—Body temperature increased—Lisinopril—systemic scleroderma	1.6e-05	0.000363	CcSEcCtD
Dexamethasone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	1.59e-05	0.000361	CcSEcCtD
Dexamethasone—Pruritus—Mycophenolic acid—systemic scleroderma	1.59e-05	0.00036	CcSEcCtD
Dexamethasone—Vomiting—Azathioprine—systemic scleroderma	1.58e-05	0.00036	CcSEcCtD
Dexamethasone—Eye disorder—Prednisone—systemic scleroderma	1.58e-05	0.000358	CcSEcCtD
Dexamethasone—NR3C2—Gene Expression—TNFSF13—systemic scleroderma	1.58e-05	0.00259	CbGpPWpGaD
Dexamethasone—Rash—Azathioprine—systemic scleroderma	1.57e-05	0.000357	CcSEcCtD
Dexamethasone—Dermatitis—Azathioprine—systemic scleroderma	1.57e-05	0.000356	CcSEcCtD
Dexamethasone—Headache—Azathioprine—systemic scleroderma	1.56e-05	0.000354	CcSEcCtD
Dexamethasone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	1.56e-05	0.000354	CcSEcCtD
Dexamethasone—Dizziness—Leflunomide—systemic scleroderma	1.55e-05	0.000353	CcSEcCtD
Dexamethasone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	1.54e-05	0.00035	CcSEcCtD
Dexamethasone—Diarrhoea—Mycophenolic acid—systemic scleroderma	1.53e-05	0.000349	CcSEcCtD
Dexamethasone—Angiopathy—Prednisone—systemic scleroderma	1.53e-05	0.000348	CcSEcCtD
Dexamethasone—Conjunctivitis—Methotrexate—systemic scleroderma	1.53e-05	0.000347	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	1.53e-05	0.000347	CcSEcCtD
Dexamethasone—Pain—Mycophenolate mofetil—systemic scleroderma	1.51e-05	0.000344	CcSEcCtD
Dexamethasone—Arrhythmia—Prednisone—systemic scleroderma	1.51e-05	0.000343	CcSEcCtD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	1.5e-05	0.00248	CbGpPWpGaD
Dexamethasone—NR3C1—AP-1 transcription factor network—CCL2—systemic scleroderma	1.5e-05	0.00248	CbGpPWpGaD
Dexamethasone—Vomiting—Leflunomide—systemic scleroderma	1.49e-05	0.00034	CcSEcCtD
Dexamethasone—Alopecia—Prednisone—systemic scleroderma	1.49e-05	0.000339	CcSEcCtD
Dexamethasone—Dizziness—Mycophenolic acid—systemic scleroderma	1.48e-05	0.000337	CcSEcCtD
Dexamethasone—Rash—Leflunomide—systemic scleroderma	1.48e-05	0.000337	CcSEcCtD
Dexamethasone—Dermatitis—Leflunomide—systemic scleroderma	1.48e-05	0.000336	CcSEcCtD
Dexamethasone—Nausea—Azathioprine—systemic scleroderma	1.48e-05	0.000336	CcSEcCtD
Dexamethasone—Headache—Leflunomide—systemic scleroderma	1.47e-05	0.000335	CcSEcCtD
Dexamethasone—Erythema—Prednisone—systemic scleroderma	1.47e-05	0.000334	CcSEcCtD
Dexamethasone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	1.46e-05	0.000331	CcSEcCtD
Dexamethasone—Asthenia—Lisinopril—systemic scleroderma	1.45e-05	0.000329	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	1.45e-05	0.000329	CcSEcCtD
Dexamethasone—CYP1A1—PPARA activates gene expression—CTGF—systemic scleroderma	1.44e-05	0.00238	CbGpPWpGaD
Dexamethasone—ANXA1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	1.44e-05	0.00236	CbGpPWpGaD
Dexamethasone—Pruritus—Lisinopril—systemic scleroderma	1.43e-05	0.000325	CcSEcCtD
Dexamethasone—Vomiting—Mycophenolic acid—systemic scleroderma	1.43e-05	0.000324	CcSEcCtD
Dexamethasone—CYP17A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.42e-05	0.00234	CbGpPWpGaD
Dexamethasone—Haemoglobin—Methotrexate—systemic scleroderma	1.42e-05	0.000322	CcSEcCtD
Dexamethasone—Rash—Mycophenolic acid—systemic scleroderma	1.41e-05	0.000321	CcSEcCtD
Dexamethasone—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	1.41e-05	0.00232	CbGpPWpGaD
Dexamethasone—Dermatitis—Mycophenolic acid—systemic scleroderma	1.41e-05	0.000321	CcSEcCtD
Dexamethasone—Haemorrhage—Methotrexate—systemic scleroderma	1.41e-05	0.000321	CcSEcCtD
Dexamethasone—Urticaria—Mycophenolate mofetil—systemic scleroderma	1.41e-05	0.000319	CcSEcCtD
Dexamethasone—Headache—Mycophenolic acid—systemic scleroderma	1.4e-05	0.000319	CcSEcCtD
Dexamethasone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	1.4e-05	0.000318	CcSEcCtD
Dexamethasone—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	1.4e-05	0.000318	CcSEcCtD
Dexamethasone—Nausea—Leflunomide—systemic scleroderma	1.4e-05	0.000317	CcSEcCtD
Dexamethasone—NOS2—Spinal Cord Injury—TGFB1—systemic scleroderma	1.39e-05	0.00229	CbGpPWpGaD
Dexamethasone—Diarrhoea—Lisinopril—systemic scleroderma	1.38e-05	0.000314	CcSEcCtD
Dexamethasone—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	1.36e-05	0.00225	CbGpPWpGaD
Dexamethasone—Ill-defined disorder—Prednisone—systemic scleroderma	1.36e-05	0.00031	CcSEcCtD
Dexamethasone—Visual impairment—Methotrexate—systemic scleroderma	1.36e-05	0.000309	CcSEcCtD
Dexamethasone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	1.35e-05	0.00223	CbGpPWpGaD
Dexamethasone—Angioedema—Prednisone—systemic scleroderma	1.34e-05	0.000305	CcSEcCtD
Dexamethasone—Dizziness—Lisinopril—systemic scleroderma	1.34e-05	0.000303	CcSEcCtD
Dexamethasone—Nausea—Mycophenolic acid—systemic scleroderma	1.33e-05	0.000303	CcSEcCtD
Dexamethasone—Malaise—Prednisone—systemic scleroderma	1.32e-05	0.000301	CcSEcCtD
Dexamethasone—NOS2—Disease—SMAD7—systemic scleroderma	1.32e-05	0.00218	CbGpPWpGaD
Dexamethasone—Vertigo—Prednisone—systemic scleroderma	1.32e-05	0.0003	CcSEcCtD
Dexamethasone—Eye disorder—Methotrexate—systemic scleroderma	1.32e-05	0.0003	CcSEcCtD
Dexamethasone—Syncope—Prednisone—systemic scleroderma	1.32e-05	0.000299	CcSEcCtD
Dexamethasone—CYP11A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.3e-05	0.00214	CbGpPWpGaD
Dexamethasone—Loss of consciousness—Prednisone—systemic scleroderma	1.29e-05	0.000294	CcSEcCtD
Dexamethasone—CYP4A11—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.29e-05	0.00212	CbGpPWpGaD
Dexamethasone—Vomiting—Lisinopril—systemic scleroderma	1.28e-05	0.000292	CcSEcCtD
Dexamethasone—Angiopathy—Methotrexate—systemic scleroderma	1.28e-05	0.000291	CcSEcCtD
Dexamethasone—Rash—Lisinopril—systemic scleroderma	1.27e-05	0.000289	CcSEcCtD
Dexamethasone—Convulsion—Prednisone—systemic scleroderma	1.27e-05	0.000289	CcSEcCtD
Dexamethasone—Dermatitis—Lisinopril—systemic scleroderma	1.27e-05	0.000289	CcSEcCtD
Dexamethasone—Asthenia—Mycophenolate mofetil—systemic scleroderma	1.27e-05	0.000288	CcSEcCtD
Dexamethasone—Hypertension—Prednisone—systemic scleroderma	1.27e-05	0.000288	CcSEcCtD
Dexamethasone—Headache—Lisinopril—systemic scleroderma	1.26e-05	0.000287	CcSEcCtD
Dexamethasone—ANXA1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.26e-05	0.00207	CbGpPWpGaD
Dexamethasone—Pruritus—Mycophenolate mofetil—systemic scleroderma	1.25e-05	0.000284	CcSEcCtD
Dexamethasone—Myalgia—Prednisone—systemic scleroderma	1.25e-05	0.000284	CcSEcCtD
Dexamethasone—Anxiety—Prednisone—systemic scleroderma	1.25e-05	0.000283	CcSEcCtD
Dexamethasone—Alopecia—Methotrexate—systemic scleroderma	1.25e-05	0.000283	CcSEcCtD
Dexamethasone—NR3C1—Generic Transcription Pathway—SMAD7—systemic scleroderma	1.24e-05	0.00204	CbGpPWpGaD
Dexamethasone—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	1.24e-05	0.00204	CbGpPWpGaD
Dexamethasone—Discomfort—Prednisone—systemic scleroderma	1.24e-05	0.000281	CcSEcCtD
Dexamethasone—Erythema—Methotrexate—systemic scleroderma	1.23e-05	0.000279	CcSEcCtD
Dexamethasone—NR0B1—Gene Expression—CTGF—systemic scleroderma	1.23e-05	0.00202	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—SMAD7—systemic scleroderma	1.23e-05	0.00202	CbGpPWpGaD
Dexamethasone—CYP11A1—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	1.22e-05	0.00201	CbGpPWpGaD
Dexamethasone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	1.21e-05	0.000275	CcSEcCtD
Dexamethasone—NOS2—Disease—TGFBI—systemic scleroderma	1.21e-05	0.00199	CbGpPWpGaD
Dexamethasone—Nausea—Lisinopril—systemic scleroderma	1.2e-05	0.000273	CcSEcCtD
Dexamethasone—Anaphylactic shock—Prednisone—systemic scleroderma	1.2e-05	0.000273	CcSEcCtD
Dexamethasone—Oedema—Prednisone—systemic scleroderma	1.2e-05	0.000273	CcSEcCtD
Dexamethasone—Infection—Prednisone—systemic scleroderma	1.19e-05	0.000271	CcSEcCtD
Dexamethasone—PGR—Generic Transcription Pathway—CTGF—systemic scleroderma	1.19e-05	0.00195	CbGpPWpGaD
Dexamethasone—Shock—Prednisone—systemic scleroderma	1.18e-05	0.000268	CcSEcCtD
Dexamethasone—Nervous system disorder—Prednisone—systemic scleroderma	1.18e-05	0.000267	CcSEcCtD
Dexamethasone—Tachycardia—Prednisone—systemic scleroderma	1.17e-05	0.000266	CcSEcCtD
Dexamethasone—Dizziness—Mycophenolate mofetil—systemic scleroderma	1.17e-05	0.000266	CcSEcCtD
Dexamethasone—Hyperhidrosis—Prednisone—systemic scleroderma	1.16e-05	0.000263	CcSEcCtD
Dexamethasone—NR3C1—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	1.15e-05	0.0019	CbGpPWpGaD
Dexamethasone—Anorexia—Prednisone—systemic scleroderma	1.14e-05	0.00026	CcSEcCtD
Dexamethasone—ABCB11—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.14e-05	0.00188	CbGpPWpGaD
Dexamethasone—Ill-defined disorder—Methotrexate—systemic scleroderma	1.14e-05	0.000259	CcSEcCtD
Dexamethasone—CYP19A1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	1.13e-05	0.00187	CbGpPWpGaD
Dexamethasone—Vomiting—Mycophenolate mofetil—systemic scleroderma	1.12e-05	0.000256	CcSEcCtD
Dexamethasone—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	1.12e-05	0.00185	CbGpPWpGaD
Dexamethasone—Rash—Mycophenolate mofetil—systemic scleroderma	1.12e-05	0.000254	CcSEcCtD
Dexamethasone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	1.11e-05	0.000253	CcSEcCtD
Dexamethasone—Headache—Mycophenolate mofetil—systemic scleroderma	1.11e-05	0.000252	CcSEcCtD
Dexamethasone—Malaise—Methotrexate—systemic scleroderma	1.11e-05	0.000252	CcSEcCtD
Dexamethasone—Vertigo—Methotrexate—systemic scleroderma	1.1e-05	0.000251	CcSEcCtD
Dexamethasone—ANXA1—GPCR ligand binding—CCL2—systemic scleroderma	1.09e-05	0.0018	CbGpPWpGaD
Dexamethasone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	1.09e-05	0.000248	CcSEcCtD
Dexamethasone—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	1.09e-05	0.0018	CbGpPWpGaD
Dexamethasone—Insomnia—Prednisone—systemic scleroderma	1.08e-05	0.000247	CcSEcCtD
Dexamethasone—CYP17A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.08e-05	0.00178	CbGpPWpGaD
Dexamethasone—Paraesthesia—Prednisone—systemic scleroderma	1.08e-05	0.000245	CcSEcCtD
Dexamethasone—NR3C1—AP-1 transcription factor network—MMP9—systemic scleroderma	1.08e-05	0.00177	CbGpPWpGaD
Dexamethasone—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	1.07e-05	0.00177	CbGpPWpGaD
Dexamethasone—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	1.07e-05	0.00176	CbGpPWpGaD
Dexamethasone—Convulsion—Methotrexate—systemic scleroderma	1.06e-05	0.000242	CcSEcCtD
Dexamethasone—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	1.06e-05	0.00175	CbGpPWpGaD
Dexamethasone—Dyspepsia—Prednisone—systemic scleroderma	1.06e-05	0.00024	CcSEcCtD
Dexamethasone—PLA2G1B—Metabolism—HSPG2—systemic scleroderma	1.05e-05	0.00173	CbGpPWpGaD
Dexamethasone—Nausea—Mycophenolate mofetil—systemic scleroderma	1.05e-05	0.000239	CcSEcCtD
Dexamethasone—Myalgia—Methotrexate—systemic scleroderma	1.05e-05	0.000238	CcSEcCtD
Dexamethasone—Decreased appetite—Prednisone—systemic scleroderma	1.04e-05	0.000237	CcSEcCtD
Dexamethasone—Fatigue—Prednisone—systemic scleroderma	1.03e-05	0.000235	CcSEcCtD
Dexamethasone—Discomfort—Methotrexate—systemic scleroderma	1.03e-05	0.000235	CcSEcCtD
Dexamethasone—PGR—Gene Expression—SMAD7—systemic scleroderma	1.03e-05	0.0017	CbGpPWpGaD
Dexamethasone—Anaphylactic shock—Methotrexate—systemic scleroderma	1e-05	0.000228	CcSEcCtD
Dexamethasone—Infection—Methotrexate—systemic scleroderma	9.96e-06	0.000226	CcSEcCtD
Dexamethasone—Feeling abnormal—Prednisone—systemic scleroderma	9.88e-06	0.000225	CcSEcCtD
Dexamethasone—CYP11A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.86e-06	0.00162	CbGpPWpGaD
Dexamethasone—Nervous system disorder—Methotrexate—systemic scleroderma	9.83e-06	0.000223	CcSEcCtD
Dexamethasone—Thrombocytopenia—Methotrexate—systemic scleroderma	9.81e-06	0.000223	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Prednisone—systemic scleroderma	9.81e-06	0.000223	CcSEcCtD
Dexamethasone—CYP4A11—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.76e-06	0.00161	CbGpPWpGaD
Dexamethasone—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	9.73e-06	0.0016	CbGpPWpGaD
Dexamethasone—Hyperhidrosis—Methotrexate—systemic scleroderma	9.69e-06	0.00022	CcSEcCtD
Dexamethasone—NOS2—Disease—HSPG2—systemic scleroderma	9.65e-06	0.00159	CbGpPWpGaD
Dexamethasone—PGR—Gene Expression—TNFSF13—systemic scleroderma	9.6e-06	0.00158	CbGpPWpGaD
Dexamethasone—Anorexia—Methotrexate—systemic scleroderma	9.55e-06	0.000217	CcSEcCtD
Dexamethasone—SLCO1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	9.54e-06	0.00157	CbGpPWpGaD
Dexamethasone—Urticaria—Prednisone—systemic scleroderma	9.53e-06	0.000217	CcSEcCtD
Dexamethasone—ANXA1—Signaling Pathways—RHOB—systemic scleroderma	9.5e-06	0.00156	CbGpPWpGaD
Dexamethasone—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	9.49e-06	0.00156	CbGpPWpGaD
Dexamethasone—Abdominal pain—Prednisone—systemic scleroderma	9.48e-06	0.000215	CcSEcCtD
Dexamethasone—Body temperature increased—Prednisone—systemic scleroderma	9.48e-06	0.000215	CcSEcCtD
Dexamethasone—NR3C2—Gene Expression—CTGF—systemic scleroderma	9.37e-06	0.00154	CbGpPWpGaD
Dexamethasone—Hypotension—Methotrexate—systemic scleroderma	9.36e-06	0.000213	CcSEcCtD
Dexamethasone—NOS2—Disease—CSK—systemic scleroderma	9.32e-06	0.00153	CbGpPWpGaD
Dexamethasone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.13e-06	0.000208	CcSEcCtD
Dexamethasone—NR3C1—Endoderm Differentiation—TGFB1—systemic scleroderma	9.07e-06	0.00149	CbGpPWpGaD
Dexamethasone—NOS2—Hemostasis—MMP1—systemic scleroderma	9.07e-06	0.00149	CbGpPWpGaD
Dexamethasone—Insomnia—Methotrexate—systemic scleroderma	9.06e-06	0.000206	CcSEcCtD
Dexamethasone—ANXA1—GPCR downstream signaling—EDN1—systemic scleroderma	9.04e-06	0.00149	CbGpPWpGaD
Dexamethasone—Paraesthesia—Methotrexate—systemic scleroderma	9e-06	0.000205	CcSEcCtD
Dexamethasone—ANXA1—Signaling Pathways—HSPG2—systemic scleroderma	8.96e-06	0.00147	CbGpPWpGaD
Dexamethasone—NR3C1—AP-1 transcription factor network—TGFB1—systemic scleroderma	8.86e-06	0.00146	CbGpPWpGaD
Dexamethasone—Dyspepsia—Methotrexate—systemic scleroderma	8.82e-06	0.0002	CcSEcCtD
Dexamethasone—NOS2—Disease—CD247—systemic scleroderma	8.76e-06	0.00144	CbGpPWpGaD
Dexamethasone—Decreased appetite—Methotrexate—systemic scleroderma	8.71e-06	0.000198	CcSEcCtD
Dexamethasone—ABCB11—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	8.66e-06	0.00143	CbGpPWpGaD
Dexamethasone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	8.65e-06	0.000197	CcSEcCtD
Dexamethasone—ANXA1—Signaling Pathways—CSK—systemic scleroderma	8.65e-06	0.00142	CbGpPWpGaD
Dexamethasone—Fatigue—Methotrexate—systemic scleroderma	8.64e-06	0.000196	CcSEcCtD
Dexamethasone—CYP19A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.62e-06	0.00142	CbGpPWpGaD
Dexamethasone—Asthenia—Prednisone—systemic scleroderma	8.6e-06	0.000196	CcSEcCtD
Dexamethasone—Pain—Methotrexate—systemic scleroderma	8.57e-06	0.000195	CcSEcCtD
Dexamethasone—Pruritus—Prednisone—systemic scleroderma	8.48e-06	0.000193	CcSEcCtD
Dexamethasone—CYP4A11—NRF2 pathway—TGFB1—systemic scleroderma	8.34e-06	0.00137	CbGpPWpGaD
Dexamethasone—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	8.34e-06	0.00137	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.3e-06	0.00137	CbGpPWpGaD
Dexamethasone—CYP3A43—Metabolism—HSPG2—systemic scleroderma	8.28e-06	0.00136	CbGpPWpGaD
Dexamethasone—Feeling abnormal—Methotrexate—systemic scleroderma	8.26e-06	0.000188	CcSEcCtD
Dexamethasone—ANXA1—Signaling by GPCR—EDN1—systemic scleroderma	8.21e-06	0.00135	CbGpPWpGaD
Dexamethasone—Diarrhoea—Prednisone—systemic scleroderma	8.2e-06	0.000186	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.19e-06	0.000186	CcSEcCtD
Dexamethasone—PLA2G1B—Metabolism—CTGF—systemic scleroderma	7.97e-06	0.00131	CbGpPWpGaD
Dexamethasone—Urticaria—Methotrexate—systemic scleroderma	7.96e-06	0.000181	CcSEcCtD
Dexamethasone—Dizziness—Prednisone—systemic scleroderma	7.93e-06	0.00018	CcSEcCtD
Dexamethasone—Body temperature increased—Methotrexate—systemic scleroderma	7.92e-06	0.00018	CcSEcCtD
Dexamethasone—Abdominal pain—Methotrexate—systemic scleroderma	7.92e-06	0.00018	CcSEcCtD
Dexamethasone—Vomiting—Prednisone—systemic scleroderma	7.62e-06	0.000173	CcSEcCtD
Dexamethasone—Rash—Prednisone—systemic scleroderma	7.56e-06	0.000172	CcSEcCtD
Dexamethasone—Dermatitis—Prednisone—systemic scleroderma	7.55e-06	0.000172	CcSEcCtD
Dexamethasone—Headache—Prednisone—systemic scleroderma	7.51e-06	0.000171	CcSEcCtD
Dexamethasone—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	7.51e-06	0.00124	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.23e-06	0.00119	CbGpPWpGaD
Dexamethasone—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	7.2e-06	0.00119	CbGpPWpGaD
Dexamethasone—Asthenia—Methotrexate—systemic scleroderma	7.19e-06	0.000163	CcSEcCtD
Dexamethasone—Nausea—Prednisone—systemic scleroderma	7.12e-06	0.000162	CcSEcCtD
Dexamethasone—Pruritus—Methotrexate—systemic scleroderma	7.09e-06	0.000161	CcSEcCtD
Dexamethasone—Diarrhoea—Methotrexate—systemic scleroderma	6.86e-06	0.000156	CcSEcCtD
Dexamethasone—NR3C1—Generic Transcription Pathway—CTGF—systemic scleroderma	6.85e-06	0.00113	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—SMAD7—systemic scleroderma	6.71e-06	0.00111	CbGpPWpGaD
Dexamethasone—Dizziness—Methotrexate—systemic scleroderma	6.63e-06	0.000151	CcSEcCtD
Dexamethasone—NOS2—Hemostasis—NOS3—systemic scleroderma	6.57e-06	0.00108	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.53e-06	0.00108	CbGpPWpGaD
Dexamethasone—Vomiting—Methotrexate—systemic scleroderma	6.37e-06	0.000145	CcSEcCtD
Dexamethasone—CYP17A1—Metabolism—HSPG2—systemic scleroderma	6.34e-06	0.00104	CbGpPWpGaD
Dexamethasone—Rash—Methotrexate—systemic scleroderma	6.32e-06	0.000144	CcSEcCtD
Dexamethasone—Dermatitis—Methotrexate—systemic scleroderma	6.31e-06	0.000143	CcSEcCtD
Dexamethasone—CYP1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.29e-06	0.00104	CbGpPWpGaD
Dexamethasone—Headache—Methotrexate—systemic scleroderma	6.28e-06	0.000143	CcSEcCtD
Dexamethasone—CYP3A43—Metabolism—CTGF—systemic scleroderma	6.27e-06	0.00103	CbGpPWpGaD
Dexamethasone—NR3C1—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	6.01e-06	0.000989	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—SMAD7—systemic scleroderma	5.97e-06	0.000982	CbGpPWpGaD
Dexamethasone—Nausea—Methotrexate—systemic scleroderma	5.95e-06	0.000135	CcSEcCtD
Dexamethasone—CYP11A1—Metabolism—HSPG2—systemic scleroderma	5.8e-06	0.000954	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.76e-06	0.000948	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—HSPG2—systemic scleroderma	5.74e-06	0.000945	CbGpPWpGaD
Dexamethasone—PGR—Gene Expression—CTGF—systemic scleroderma	5.71e-06	0.00094	CbGpPWpGaD
Dexamethasone—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	5.69e-06	0.000937	CbGpPWpGaD
Dexamethasone—ABCC2—NRF2 pathway—TGFB1—systemic scleroderma	5.63e-06	0.000926	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling by GPCR—CCL2—systemic scleroderma	5.61e-06	0.000924	CbGpPWpGaD
Dexamethasone—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	5.56e-06	0.000916	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—TNFSF13—systemic scleroderma	5.55e-06	0.000913	CbGpPWpGaD
Dexamethasone—NR3C1—Adipogenesis—TGFB1—systemic scleroderma	5.4e-06	0.000889	CbGpPWpGaD
Dexamethasone—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	5.37e-06	0.000884	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—RHOB—systemic scleroderma	5.19e-06	0.000855	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.11e-06	0.000842	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—HSPG2—systemic scleroderma	5.09e-06	0.000838	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—HSPG2—systemic scleroderma	4.9e-06	0.000806	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—EDN1—systemic scleroderma	4.85e-06	0.000798	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—CTGF—systemic scleroderma	4.8e-06	0.000791	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CSK—systemic scleroderma	4.73e-06	0.000779	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.69e-06	0.000772	CbGpPWpGaD
Dexamethasone—CYP2A6—NRF2 pathway—TGFB1—systemic scleroderma	4.44e-06	0.000732	CbGpPWpGaD
Dexamethasone—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	4.42e-06	0.000728	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—CTGF—systemic scleroderma	4.39e-06	0.000723	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.37e-06	0.000719	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—CTGF—systemic scleroderma	4.35e-06	0.000716	CbGpPWpGaD
Dexamethasone—NOS2—Hemostasis—TGFB1—systemic scleroderma	4.35e-06	0.000716	CbGpPWpGaD
Dexamethasone—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	4.32e-06	0.000712	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—HSPG2—systemic scleroderma	4.25e-06	0.000699	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—SMAD7—systemic scleroderma	4.2e-06	0.000691	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.18e-06	0.000689	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.87e-06	0.000638	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—CTGF—systemic scleroderma	3.86e-06	0.000635	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—TGFBI—systemic scleroderma	3.84e-06	0.000632	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—HSPG2—systemic scleroderma	3.84e-06	0.000632	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.82e-06	0.000628	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—HSPG2—systemic scleroderma	3.7e-06	0.000609	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.55e-06	0.000585	CbGpPWpGaD
Dexamethasone—PLA2G1B—Metabolism—NOS3—systemic scleroderma	3.47e-06	0.000571	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—HSPG2—systemic scleroderma	3.36e-06	0.000554	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—HSPG2—systemic scleroderma	3.33e-06	0.000549	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—CCL2—systemic scleroderma	3.32e-06	0.000546	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—CTGF—systemic scleroderma	3.3e-06	0.000543	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—CTGF—systemic scleroderma	3.22e-06	0.00053	CbGpPWpGaD
Dexamethasone—NOS2—Disease—NOS3—systemic scleroderma	3.18e-06	0.000524	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.17e-06	0.000522	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—HSPG2—systemic scleroderma	3.06e-06	0.000504	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—HSPG2—systemic scleroderma	3.06e-06	0.000503	CbGpPWpGaD
Dexamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	3.01e-06	0.000495	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CSK—systemic scleroderma	2.96e-06	0.000487	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—NOS3—systemic scleroderma	2.95e-06	0.000486	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—CTGF—systemic scleroderma	2.91e-06	0.000479	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.89e-06	0.000476	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—CTGF—systemic scleroderma	2.8e-06	0.000461	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CD247—systemic scleroderma	2.78e-06	0.000458	CbGpPWpGaD
Dexamethasone—CYP3A43—Metabolism—NOS3—systemic scleroderma	2.73e-06	0.00045	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—EDN1—systemic scleroderma	2.65e-06	0.000436	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—HSPG2—systemic scleroderma	2.57e-06	0.000422	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—CTGF—systemic scleroderma	2.55e-06	0.00042	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—CTGF—systemic scleroderma	2.53e-06	0.000416	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—HSPG2—systemic scleroderma	2.47e-06	0.000406	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—HSPG2—systemic scleroderma	2.42e-06	0.000398	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—HSPG2—systemic scleroderma	2.41e-06	0.000397	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—MMP9—systemic scleroderma	2.37e-06	0.00039	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—CTGF—systemic scleroderma	2.32e-06	0.000381	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—HSPG2—systemic scleroderma	2.28e-06	0.000375	CbGpPWpGaD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.13e-06	0.000351	CbGpPWpGaD
Dexamethasone—NOS2—Disease—TGFB1—systemic scleroderma	2.1e-06	0.000346	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—NOS3—systemic scleroderma	2.09e-06	0.000344	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—HSPG2—systemic scleroderma	2.09e-06	0.000344	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—TGFB1—systemic scleroderma	1.95e-06	0.000322	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—CTGF—systemic scleroderma	1.94e-06	0.00032	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—NOS3—systemic scleroderma	1.91e-06	0.000315	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—NOS3—systemic scleroderma	1.89e-06	0.000312	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—CTGF—systemic scleroderma	1.87e-06	0.000308	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—HSPG2—systemic scleroderma	1.86e-06	0.000307	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—CTGF—systemic scleroderma	1.83e-06	0.000301	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—CTGF—systemic scleroderma	1.83e-06	0.000301	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.82e-06	0.000299	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CCL2—systemic scleroderma	1.81e-06	0.000298	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—CTGF—systemic scleroderma	1.73e-06	0.000284	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.71e-06	0.000282	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—HSPG2—systemic scleroderma	1.7e-06	0.00028	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—NOS3—systemic scleroderma	1.68e-06	0.000276	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—NOS3—systemic scleroderma	1.62e-06	0.000266	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CTGF—systemic scleroderma	1.58e-06	0.00026	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CTGF—systemic scleroderma	1.41e-06	0.000232	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—NOS3—systemic scleroderma	1.4e-06	0.000231	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CTGF—systemic scleroderma	1.38e-06	0.000227	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.3e-06	0.000214	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MMP9—systemic scleroderma	1.3e-06	0.000213	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CTGF—systemic scleroderma	1.29e-06	0.000212	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—NOS3—systemic scleroderma	1.27e-06	0.000209	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—NOS3—systemic scleroderma	1.22e-06	0.000201	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.12e-06	0.000184	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—NOS3—systemic scleroderma	1.11e-06	0.000183	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—NOS3—systemic scleroderma	1.1e-06	0.000181	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—TGFB1—systemic scleroderma	1.07e-06	0.000176	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—NOS3—systemic scleroderma	1.01e-06	0.000166	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—NOS3—systemic scleroderma	1.01e-06	0.000166	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CTGF—systemic scleroderma	8.49e-07	0.00014	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—NOS3—systemic scleroderma	8.46e-07	0.000139	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—NOS3—systemic scleroderma	8.13e-07	0.000134	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—NOS3—systemic scleroderma	7.97e-07	0.000131	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—NOS3—systemic scleroderma	7.95e-07	0.000131	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—NOS3—systemic scleroderma	7.51e-07	0.000124	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—NOS3—systemic scleroderma	6.89e-07	0.000113	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—TGFB1—systemic scleroderma	6.68e-07	0.00011	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—NOS3—systemic scleroderma	6.15e-07	0.000101	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—NOS3—systemic scleroderma	6e-07	9.88e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—NOS3—systemic scleroderma	5.65e-07	9.31e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—NOS3—systemic scleroderma	5.6e-07	9.23e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—NOS3—systemic scleroderma	3.7e-07	6.08e-05	CbGpPWpGaD
